| [1] |
Cauley JA, Chalhoub D, Kassem AM, et al. Geographic and ethnic disparities in osteoporotic fractures[J]. Nat Rev Endocrinol, 2014, 10 (6): 338-351.
|
| [2] |
贺丽英，孙蕴，要文娟，等. 2010-2016年中国老年人骨质疏松症患病率meta分析[J].中国骨质疏松杂志，2016，22（12）：1590-1596.
|
| [3] |
陈良，陈巧杰，武少坤，等.老年骨质疏松性踝关节骨折手术治疗41例分析[J/CD].中华危重症医学杂志（电子版），2015，8（2）：120-122.
|
| [4] |
陈叶海，杨俊涛，黄明伟，等.编织网袋在伴有后壁破裂脊柱骨质疏松性骨折中的应用[J/CD].中华危重症医学杂志（电子版）2016，9（5）：297-299.
|
| [5] |
李江伟，叶川，孙立.生物型与骨水泥半髋置换治疗老年股骨颈骨折的对比观察[J/CD].中华危重症医学杂志（电子版），2014，8（1）：35-37.
|
| [6] |
Black DM, Cummings SR, Karpf DB, et al. Random-ised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group[J]. Lancet, 1996, 348 (9041): 1535-1541.
|
| [7] |
Lau EM, Woo J, Chan YH, et al. Alendronate prev-ents bone loss in Chinese women with osteoporosis[J]. Bone, 2000, 27 (5): 677-680.
|
| [8] |
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med, 2007, 356 (18): 1809-1822.
|
| [9] |
Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zo-ledronic acid and clinical fractures and mortality after hip fracture[J]. N Engl J Med, 2007, 357 (18): 1799-1809.
|
| [10] |
Giger EV, Castagner B, Leroux JC. Biomedical app-lications of bisphosphonates[J]. J Control Release, 2013,167 (2): 175-188.
|
| [11] |
Kanis JA, Reginster JY, Kaufman JM, et al. A re-appraisal of generic bisphosphonates in osteoporosis[J]. Osteoporos Int, 2012, 23 (1): 213-221.
|
| [12] |
Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study[J]. JAMA Intern Med, 2014, 174 (7): 1126-1134.
|
| [13] |
Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis[J]. N Engl J Med, 2012 367 (18): 1714-1723.
|
| [14] |
Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study[J]. J Bone Miner Res, 2010, 25 (10): 2239-2250.
|
| [15] |
McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate[J]. Bone, 2007, 41 (1): 122-128.
|
| [16] |
Hadji P, Gamerdinger D, Spieler W, et al. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass[J]. Osteoporos Int, 2012, 23 (2): 625-633.
|
| [17] |
Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density[J]. Bone, 2007, 40 (5): 1238-1243.
|
| [18] |
Tan W, Sun J, Zhou L, et al. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis[J]. J Clin Pharm Ther, 2016, 41 (5): 519-523.
|
| [19] |
Al-Bogami MM, Alkhorayef MA, Bystrom J, et al. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate[J]. Saudi Med J, 2015, 36 (11): 1305-1311.
|